Intelerad Acquires PenRad to Expand Breast Imaging and Lung Screening Capabilities

Intelerad Medical Systems (Raleigh, NC, USA), a leading global provider of enterprise medical imaging solutions, has acquired PenRad Technologies, Inc. (Buffalo, MN, USA), a software provider for enhancing productivity for breast imaging and lung screening. The acquisition will expand Intelerad’s product offerings for mammography and lung analytics, optimizing workflows for radiologists and boosting health outcomes for patients.

The mammography market is expected to increase by more than 20% in the next several years, while the lung cancer diagnostics market is expected to reach USD 3.4 billion by 2026. Cancer screenings, and most notably, mammograms, drastically decreased during the COVID-19 pandemic as many healthcare facilities were temporarily closed and others faced severe staffing shortages. As the demand for scans continues to rise to pre-pandemic levels, innovative tools and technologies are critical to ensuring providers can meet the influx of patients, and that such screenings and scans are readily available to further improve overall health outcomes.

PenRad’s three core product offerings – PenRad for breast imaging, PenLung for lung screening, and PenTrac for patient tracking and reporting – have a proven track record of eliminating overhead costs, decreasing liability exposure and increasing patient satisfaction for innovative enterprise systems and diagnostic imaging centers and facilities. With the company’s next-generation technology and dedicated client support, PenRad is leading the way in automated diagnostic radiology. As global demand for scalable imaging and workflow solutions continues to increase, Intelerad will continue to fulfill its mission of providing clients with one of the most scalable imaging platforms in the world, enabling them to drive clinical efficiency and focus on providing enhanced patient care.

“Cancer affects all of us, whether you’ve personally been diagnosed or have witnessed a family member, friend or loved one suffer from the disease. PenRad was founded to help drive actionable change for not only my own family's breast cancer, but for millions of other individuals,” said Greg Gustafson, Founder and President of PenRad. “As our company heads into this next chapter, I’m excited to partner with Intelerad to further grow, scale, and impact patient lives and the healthcare industry at large.”

“The acquisition of PenRad is an exciting milestone for Intelerad. Our global team of dreamers and doers are committed to improving healthcare through innovative technology, which means delivering the best-in-class systems our industry needs to improve the overall health of all populations,” said Mike Lipps, CEO, Intelerad. “Lung and breast cancer impact millions of individuals, and screenings play a major role in saving lives. By integrating PenRad’s core solutions into our company, we can ensure all patients have access to the scans they need to decrease health risks, while at the same time offering healthcare systems greater productivity.”

Visit expo >

Gold Member

Solid State Kv/Dose Multi-Sensor

AGMS-DM+

New

Silver Member

Radiographic Positioning Equipment

2-Step Multiview Positioning Platform

New

Mobile Digital X-Ray System

MobileDiagnost wDR 2.1

Ultrasound System

Voluson Signature 18